Skip NavigationSkip to Content

Human Erythrocyte Glycolipids Promote Hiv-1 Envelope Glycoprotein-Mediated Fusion of Cd4(+) Cells

  1. Author:
    Puri, A.
    Hug, P.
    Munozbarroso, I.
    Blumenthal, R.
    1. Year: 1998
  1. Journal: Biochemical and Biophysical Research Communications
    1. 242
    2. 1
    3. Pages: 219-225
  2. Type of Article: Article
  1. Abstract:

    We examined the role of target membrane glycolipids in CD4-mediated HIV-1 fusion by altering the glycolipid levels in CD4(+) cells. CD4(+) human cells exhibited 50% reduction in extent of fusion with gp120-gp41 expressing cells (TF228) when grown in the presence of a glycolipid synthesis inhibitor PPMP. We added erythrocyte glycolipids (GL) to fusion-incompetent CD4(+) non-human cells by influenza-hemagglutinin-mediated fusion between GL-containing liposomes and target cells. Human erythrocyte GL (HuGL)-modified CD4(+) non-human cells became susceptible to fusion with TF228 cells. Transfer of bovine erythrocyte glycolipids (BoGL) to CD4(+) non-human cells under similar conditions did not complement HIV-1 fusion, Furthermore, addition of HuGL, but not BoGL, to PPMP-inhibited cells rescued fusion to the original levels. Our observations demonstrate that human erythrocyte glycolipids promote CD4-mediated HIV-1 fusion and certain glycolipid(s) from human erythrocytes may serve as alternative and/or additional cofactors in HIV-1 entry. (C) 1998 Academic Press. [References: 26]

    See More

External Sources

  1. No sources found.

Library Notes

  1. No notes added.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel